文献速递角膜与眼表疾病眼整形与眼眶

急性期伴眼部受累的Stevens-Johnson综合征和中毒性表皮坏死松解症的局部倍他米松治疗

Topical Betamethasone Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Ocular Involvement in the Acute Phase.
PubMed 文献 · Am J Ophthalmol · 2023-05-12

该回顾性病例系列分析了2006年7月至2017年7月京都府立医科大学附属医院收治的13例急性期伴眼部受累的SJS/TEN患者,发现激素冲击治疗后眼表炎症仍持续,泪液中出现细胞因子风暴,而局部倍他米松联合全身激素治疗下最终随访未见严重眼部后遗症。

要点

  • 在10例记录激素治疗前临床过程的病例中,最严重期平均急性眼部严重程度评分(AOSS)为2.8±0.4分。
  • 最严重期平均全身激素剂量(激素冲击治疗后)为694±386 mg,局部激素(0.1%倍他米松滴眼液和眼膏)平均每日13.4±3.3次。
  • 4例细胞因子分析显示激素冲击治疗后泪液中出现细胞因子风暴,提示眼表炎症持续。

核心结论

  • 在SJS/TEN患者中,激素冲击治疗后全身炎症改善后眼表炎症仍然强烈,因此建议适当给予全身和局部激素治疗。

研究设计与样本

  • 回顾性病例系列,纳入2006年7月至2017年7月在日本京都府立医科大学附属医院治疗的急性SJS/TEN患者13例,回顾性检查眼部表现、局部激素剂量、全身激素剂量及眼部后遗症,并分析泪液和血清样本中的细胞因子水平。

主要发现

  • 在10例记录激素治疗前临床过程的病例中,最严重期平均AOSS为2.8±0.4分(AOSS:3=非常严重;2=严重;1=轻度;0=无)。
  • 最严重期平均全身激素剂量(激素冲击治疗后)为694±386 mg,平均局部激素(0.1%倍他米松滴眼液和眼膏)剂量为每日13.4±3.3次。
  • 4例细胞因子水平分析显示激素冲击治疗后泪液中出现细胞因子风暴。
  • 最终随访时,8例患者的16只眼logMAR视力≤0,未观察到严重眼部后遗症。

临床怎么用

  • 作者认为,SJS/TEN患者激素冲击治疗后全身炎症改善后眼表炎症仍强烈,因此应适当给予全身和局部激素治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To clarify the importance of administering topical steroids for the treatment of Stevens-Johnson syndrome (SJS) / toxic epidermal necrolysis (TEN) with ocular involvement in the acute phase. DESIGN: Retrospective case series. METHODS: Using the medical records of acute SJS/TEN patients treated at the Kyoto Prefectural University of Medicine Hospital, Kyoto, Japan, between July 2006 and July 2017, the ocular findings, topical steroid dosage, systemic steroid dosage, and ocular sequelae were retrospectively examined. The level of cytokines in tear fluid and serum samples was also analyzed. RESULTS: This study involved 13 cases. In 10 cases in whom the clinical courses were recorded before the start of steroid therapy, the mean acute ocular severity score (AOSS: 3 = very severe; 2 = severe; 1 = mild; 0 = none) was 2.8 ± 0.4 points in the severest phase. The mean systemic steroid dose after steroid pulse therapy was 694 ± 386 mg and the mean topical steroid (0.1% betamethasone eye drop and ointment) dose was 13.4 ± 3.3 times daily in the severest phase. Analysis of cytokine levels of 4 cases showed that a cytokine storm occurred in the tear fluid after the steroid pulse therapy. At final follow-up, 16 eyes of 8 patients had a logMAR visual acuity of ≤0, and no serious ocular sequelae were observed. CONCLUSIONS: In patients with SJS/TEN, ocular surface inflammation remains strong even after systemic inflammation has improved post steroid pulse therapy, thus suggesting that both systemic and topical steroid therapy should be administered appropriately.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Matsumoto K, Ueta M, Inatomi T, et al. Topical Betamethasone Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Ocular Involvement in the Acute Phase. Am J Ophthalmol. 2023. PMID: 37182731. doi:10.1016/j.ajo.2023.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。